Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells

Cell Death and Disease

Volumn 6, Issue 2, 2015, Pages

  Jiang, L ^a   Dong, P ^a   Zhang, Z ^a   Li, C ^a   Li, Y ^a   Liao, Y ^a   Li, X ^a   Wu, Z ^a   Guo, S ^a   Mai, S ^a   Xie, D ^a   Liu, Z ^a   Zhou, F ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROHIBITIN; PROHIBITIN 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; REPRESSOR PROTEIN;

ADULT; ARTICLE; BLADDER CANCER; CANCER PROGNOSIS; CANCER TISSUE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; BLADDER TUMOR; CELL SURVIVAL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOCHONDRIA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84927631592     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.40     Document Type: Article

References (50)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
2. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-toepithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271-11278.
3. Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol 2011; 196: 117-122.
4. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol 2012; 188: 615-623.
5. Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology 2010; 57: 1-13.
6. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Drager BJ, Goebell PJ et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010; 28: 389-400.
7. Theiss AL, Sitaraman SV. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 2011; 1813: 1137-1143.
8. McClung JK, Jupe ER, Liu XT, Dell'Orco RT. Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 1995; 30: 99-124.
9. Mishra S, Murphy LC, Nyomba BL, Murphy LJ. Prohibitin: a potential target for new therapeutics. Trends Mol Med 2005; 11: 192-197.
10. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin: a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 1999; 18: 3501-3510.
11. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 2002; 21: 8388-8396.
12. Artal-Sanz M, Tsang WY, Willems EM, Grivell LA, Lemire BD, van der Spek H et al. The mitochondrial prohibitin complex is essential for embryonic viability and germline function in Caenorhabditis elegans. J Biol Chem 2003; 278: 32091-32099.
13. Park SE, Xu J, Frolova A, Liao L, O'Malley BW, Katzenellenbogen BS. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol Cell Biol 2005; 25: 1989-1999.
14. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Lower B, Wunderlich FT et al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev 2008; 22: 476-488.
15. Schleicher M, Shepherd BR, Suarez Y, Fernandez-Hernando C, Yu J, Pan Y et al. Prohibitin-1 maintains the angiogenic capacity of endothelial cells by regulating mitochondrial function and senescence. J Cell Biol 2008; 180: 101-112.
16. Ikonen E, Fiedler K, Parton RG, Simons K. Prohibitin an antiproliferative protein, is localized to mitochondria. FEBS Lett 1995; 358: 273-277.
17. Merkwirth C, Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim Biophys Acta 2009; 1793: 27-32.
18. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003; 278: 47853-47861.
19. Dong P, Jiang L, Liu J, Wu Z, Guo S, Zhang Z et al. Induction of paclitaxel resistance by ERalpha mediated prohibitin mitochondrial-nuclear shuttling. PLoS One 2013; 8: e83519.
20. Rajalingam K, Rudel T. Ras-Raf signaling needs prohibitin. Cell Cycle 2005; 4: 1503-1505.
21. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 2005; 7: 837-843.
22. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
23. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012; 4: a011189.
24. Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D et al. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem 2013; 20: 1923-1945.
25. Han EK, McGonigal T, Butler C, Giranda VL, Luo Y. Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells. Anticancer Res 2008; 28: 957-963.
26. Zhou TB, Qin YH. Signaling pathways of prohibitin and its role in diseases. J Recept Signal Transduct Res 2013; 33: 28-36.
27. Wu TF, Wu H,Wang YW, Chang TY, Chan SH, Lin YP et al. Prohibitin in the pathogenesis of transitional cell bladder cancer. Anticancer Res 2007; 27: 895-900.
28. Asamoto M, Cohen SM. Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines. Cancer Lett 1994; 83: 201-207.
29. Kathiria AS, Butcher LD, Feagins LA, Souza RF, Boland CR, Theiss AL. Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One 2012; 7: e31231.
30. Ahn CS, Lee JH, Reum Hwang A, Kim WT, Pai HS. Prohibitin is involved in mitochondrial biogenesis in plants. Plant J 2006; 46: 658-667.
31. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28: 305-316.
32. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-10985.
33. Ande SR, Mishra S. Prohibitin interacts with phosphatidylinositol 3,4,5-triphosphate (PIP3) and modulates insulin signaling. Biochem Biophys Res Commun 2009; 390: 1023-1028.
34. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68: 2366-2374.
35. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010; 19: 1355-1366.
36. Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113: 1723-1729.
37. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
38. Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwagi A et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000; 275: 36108-36115.
39. Xue Y, Ren J, Gao X, Jin C, Wen L, Yao X. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics 2008; 7: 1598-1608.
40. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W et al. Expression of estrogen receptorsalpha and-beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106: 2610-2616.
41. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003; 22: 7998-8011.
42. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
43. Sripathi SR, He W, Atkinson CL, Smith JJ, Liu Z, Elledge BM et al. Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry 2011; 50: 8342-8351.
44. Ande SR, Gu Y, Nyomba BL, Mishra S. Insulin induced phosphorylation of prohibitin at tyrosine 114 recruits Shp1. Biochim Biophys Acta 2009; 1793: 1372-1378.
45. Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW et al. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 2000; 19: 2444-2451.
46. Sanchez-Quiles V, Santamaria E, Segura V, Sesma L, Prieto J, Corrales FJ. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics 2010; 10: 1609-1620.
47. Mishra S, Murphy LC, Murphy LJ. The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 2006; 10: 353-363.
48. Bavelloni A, Piazzi M, Faenza I, Raffini M, D'Angelo A, Cattini L et al. Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. FASEB J 2014; 28(5): 2009-2019.
49. Sun L, Cao X, Liu B, Huang H, Wang X, Sui L et al. CaMK IV phosphorylates prohibitin 2 and regulates prohibitin 2-mediated repression of MEF2 transcription. Cell Signal 2011; 23: 1686-1690.
50. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS et al. Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer 2006; 94: 108-114.